Loading...
XLONGDR
Market cap15mUSD
Dec 23, Last price  
2.29GBP
1D
0.44%
1Q
28.65%
Jan 2017
-96.18%
IPO
-98.60%
Name

Genedrive PLC

Chart & Performance

D1W1MN
XLON:GDR chart
P/E
—
P/S
2,482.62
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
48.41%
Rev. gr., 5y
-26.66%
Revenues
501k
+810.91%
901,0001,357,0002,065,0003,968,0005,740,0005,752,0005,560,0005,356,0005,761,0004,517,0005,063,0002,619,0001,938,0002,362,0001,059,000687,00049,00055,000501,000
Net income
-7m
L+37.38%
-867,000-1,037,000-1,154,00083,000290,000385,000-244,000-1,163,000-1,693,000-3,025,000-5,915,000-6,586,000-7,030,000-3,636,000-19,419,000-691,000-4,675,000-5,150,000-7,075,000
CFO
-4m
L-0.21%
-873,000-804,000-1,131,0001,894,000-715,000-699,000-271,000-612,000-1,092,000-3,306,000-3,501,000-1,837,000-2,547,000-3,621,000-3,788,000-5,184,000-4,610,000-3,776,000-3,768,000
Earnings
Mar 26, 2025

Profile

genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.
URL
http://www.genedriveplc.com/
IPO date
Apr 04, 2007
Employees
40
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
501
810.91%
55
12.24%
49
-92.87%
Cost of revenue
5,813
5,279
9,285
Unusual Expense (Income)
NOPBT
(5,312)
(5,224)
(9,236)
NOPBT Margin
Operating Taxes
(675)
(831)
(956)
Tax Rate
NOPAT
(4,637)
(4,393)
(8,280)
Net income
(7,075)
37.38%
(5,150)
10.16%
(4,675)
576.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,253
1,685
6,694
BB yield
Debt
Debt current
19
222
16
Long-term debt
19
38
16
Deferred revenue
Other long-term liabilities
Net debt
(5,150)
(2,341)
(4,557)
Cash flow
Cash from operating activities
(3,768)
(3,776)
(4,610)
CAPEX
(29)
(52)
(62)
Cash from investing activities
1,000
(37)
45
Cash from financing activities
6,364
1,824
6,575
FCF
(4,435)
(3,747)
(8,228)
Balance
Cash
5,188
2,601
4,589
Long term investments
Excess cash
5,163
2,598
4,587
Stockholders' equity
(49,297)
(51,099)
(46,619)
Invested Capital
54,675
53,381
52,246
ROIC
ROCE
EV
Common stock shares outstanding
189,302
94,165
84,860
Price
Market cap
EV
EBITDA
(5,065)
(4,970)
(8,986)
EV/EBITDA
Interest
12
31
16
Interest/NOPBT